KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020)

Historic Short term Debt for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q1 2020 value amounting to $15.7 million.

  • Xenon Pharmaceuticals' Short term Debt changed N/A to $15.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2019, which is N/A changed from last year.
  • As of Q1 2020, Xenon Pharmaceuticals' Short term Debt stood at $15.7 million.
  • In the past 5 years, Xenon Pharmaceuticals' Short term Debt registered a high of $15.7 million during Q1 2020, and its lowest value of $700000.0 during Q4 2017.
  • Its 4-year average for Short term Debt is $4.7 million, with a median of $2.8 million in 2019.